Management of non-muscle-invasive (Superficial) bladder cancer

Seminars in Oncology

Volumn 39, Issue 5, 2012, Pages 559-572

  Nargund, Vinod H ^a   Tanabalan, C K ^a   Kabir, M N ^a  

^a HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APAZIQUONE; BCG VACCINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; MITOMYCIN C; THIOTEPA; VALRUBICIN;

ARTICLE; BLADDER CANCER; BLADDER PERFORATION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER SURGERY; CCOMPUTED TOMOGRAPHIC UROGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CYSTECTOMY; CYSTOSCOPY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; HEMATURIA; HUMAN; IMMUNOMODULATION; INTERMETHOD COMPARISON; INTRAVENOUS UROGRAPHY; LOWER URINARY TRACT SYMPTOM; NERVE STIMULATION; NON MUSCLE INVASIVE SUPERFICIAL BLADDER CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE; TUMOR BIOPSY; URINARY TRACT INFECTION; URINE CYTOLOGY; UROGRAPHY;

HUMANS; MUSCLE, SKELETAL; NEOPLASM INVASIVENESS; URINARY BLADDER NEOPLASMS;

EID: 84866972331     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2012.08.001     Document Type: Article

References (87)

1. M.F. Botteman, C.L. Pashos, A. Redaelli The health economics of bladder cancer: a comprehensive review of the published literature Pharmacoeconomics 21 2003 1315 1330
2. R. Chou, T. Dana Screening adults for bladder cancer: a review of the evidence for the U.S. Preventive Services Task Force Ann Intern Med 153 2010 461 468
3. G.L. Brodsky Pathology of bladder carcinoma Hematol Oncol Clin North Am 6 1992 59 80
4. N.M. Heney Natural history of superficial bladder cancer Prognostic features and long-term disease course Urol Clin North Am 19 1992 429 434
5. D.S. Kaufman, W.U. Shipley, A.S. Feldman Bladder cancer Lancet 374 2009 239 249
6. J.I. Epstein, M.B. Amin, V.R. Reuter, F.K. Mostofi The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder Bladder Consensus Conference Committee Am J Surg Pathol 22 1998 1435 1448
7. R.J.M. Lammers, W.P.J. Witjes, K. Hendricksen Smoking status is a risk factor for recurrence after transurethral resection of non-muscle-invasive bladder cancer Eur Urol 60 2011 713 720
8. E. Pasin, D.Y. Josephson, A.P. Mitra, J.P. Cote RJ Stein Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history Rev Urol 10 2008 31 43
9. International Agency for Research on Cancer Evaluation of the carcinogenic risk of chemicals to humans Tobacco smoking Vol. 38 1986 International Agency for Research on Cancer Lyon, France
10. A.S. Morrison Advances in the etiology of urothelial cancer Urol Clin North Am 11 1984 557 566
11. R.A.M. Case, M.E. Hosker, D.B. MacDonald Tumours of the urinary bladder in workmen engaged in the manufacture and use of certain dyestuff intermediates in the British chemical industry Br J Ind Med 11 1954 75 104
12. Y. Lotan, C.G. Roehrborn Sensitivity and specificity of commonly available bladder tumour markers versus cytology: results of a comprehensive literature review and meta-analyses Urology 61 2003 109 118
13. D. Tilki, M. Burger, G. Dalbagni Urine markers for detection and surveillance of non-muscle-invasive bladder cancer Eur Urol 60 2011 484 492
14. B.W.G. Van Rhijn, H.G. van der Poel, T.H. van der Kwast Cytology and urinary markers for the diagnosis of bladder cancer Eur Urol Suppl 8 2009 536 541
15. R. Vikram, C.M. Sandler, C.S. Ng Imaging and staging of transitional cell carcinoma: part 2, upper urinary tract - review AJR Am J Roentgenol 192 2009 1488 1493
16. A.E.T. Jacques, R.H. Reznik Radiological investigations in urological cancer V.H. Nargund, D. Raghavan, H. Sandler, Urological oncology 2008 Springer-Verlag London, UK 61 106
17. R. Vikram, C.M. Sandler, C.S. Ng Imaging and staging of transitional cell carcinoma: part 1, lower urinary tract - review AJR Am J Roentgenol 192 2009 1481 1487
18. M. Brausi, L. Collette, K. Kurth EORTC Genito-Urinary Tract Cancer Collaborative Group Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies Eur Urol 41 2002 523 531
19. J.M. Holzbeierlein, J.A. Smith Jr Surgical management of noninvasive bladder cancer (stages Ta/T1/CIS) Urol Clin North Am 27 2000 15 24
20. M. Babjuk, W. Oosterlinck, R. Sylvester EAU guidelines on nonmuscle-invasive urothelial carcinoma of the bladder Eur Urol 54 2008 303 314
21. P. Mariappan, A. Zachou, K.M. Grigor Edinburgh Uro-Oncology Group Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience Eur Urol 57 2010 843 849
22. M. Soloway, J. Patel Surgical techniques for endoscopic resection of bladder cancer Urol Clin North Am 19 1992 467 471
23. L.A.L.M. Kiemeney, J.A. Witjes, R.P. Heijbroek Should random urothelial biopsies be taken from patients with primary superficial bladder cancer? A decision analysis Br J Urol 73 1994 164 167
24. B. Moskovitz, D.R. Levin Intravesical irrigation with distilled water during and immediately after transurethral resection and later for superficial bladder cancer Eur Urol 13 1987 7 9
25. T. Onishi, T. Sasaki, A. Hoshina, T. Yabana Continuous saline bladder irrigation after transurethral resection is a prophylactic treatment choice for non-muscle invasive bladder tumor Anticancer Res 31 2011 1471 1474
26. H.B. Grossman Improving the management of bladder cancer with fluorescence cystoscopy J Environ Pathol Toxicol Oncol 26 2007 143 147
27. J.A. Witjes, J. Douglass The role of hexaminolevulinate fluorescence cystoscopy in bladder cancer Nat Clin Pract Urol 4 2007 542 549
28. P. Jichlinski, D. Jacqmin Photodynamic diagnosis in non-muscle-invasive bladder cancer Eur Urol Suppl 7 2008 529 535
29. H.W. Herr, M.S. Donat Quality control in transurethral resection of bladder tumors BJU Int 102 2008 1242 1246
30. O. Traxer, F. Pasqui, B. Gattegno, M.S. Pearle Technique and complications of transurethral surgery for bladder tumours BJU Int 94 2004 492 496
31. R.G. Hahn Fluid absorption in endoscopic surgery Br J Anaesth 96 2006 8 20
32. A. Collado, G.E. Cechile, J. Salvador, J. Vicente Early complications of endoscopic treatment for superficial bladder tumors J Urol 164 2000 1529 1532
33. A. Dick, R. Barnes, H. Hadley, R.T. Bergman, C.A. Ninan Complications of transurethral resection of bladder tumors: prevention, recognition and treatment J Urol 124 1980 810 811
34. J.M. McKiernan, S.A. Kaplan, R.P. Santarosa, A.E. Te, I.S. Sawczuk Transurethral electrovaporization of bladder cancer Urology 48 1996 207 210
35. D. Patel, B. Shah, B.M. Patel Contribution of the obturator nerve block in the transurethral resection of bladder tumours Indian J Anaesth 48 2004 47 49
36. Bladder cancer treatment PDQ - National Cancer Institute, USA www.cancer.gov/cancertopics
37. Urinary bladder S.B. Edge, D.R. Byrd, C.C. Compton AJCC cancer staging manual 7th ed. 2010 Springer New York 497 505
38. M. Kogevinas, A. 't Mannetje, S. Cordier Occupation and bladder cancer among men in Western Europe Cancer Causes Control 14 2003 907 914
39. A.F. Althausen, G.R. Prout Jr, J.J. Daly Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ J Urol 116 1976 575 580
40. N.M. Heney, S. Ahmed, M.J. Flanagan Superficial bladder cancer: progression and recurrence J Urol 130 1983 1083 1086
41. T. Lebret, D. Bohin, Z. Kassardjian Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guérin instillations J Urol 163 2000 63 67
42. R.J. Sylvester, A. van der Meijden, J.A. Witjes High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder Urology 66 2005 90 100
43. A. van der Meijden, R. Sylvester, L. Collette The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer trials J Urol 164 2000 1533 1537
44. X.R. Wu Urothelial tumorigenesis: a tale of divergent pathways Natl Rev Cancer 5 2005 713 725
45. N. Miyao, Y.C. Tsai, S.P. Lerner Role of chromosome 9 in human bladder cancer Cancer Res 53 1993 4066 4070
46. B. Czerniak, V. Chaturvedi, L. Li Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer Oncogene 18 1999 1185 1196
47. T. Wada, P. Berggren, G. Steineck Bladder neoplasms - regions at chromosome 9 with putative tumour suppressor genes Scand J Urol Nephrol 37 2003 106 111
48. A.P. Mitra, R.H. Datar, R.J. Cote Molecular staging of bladder cancer BJU Int 96 2005 7 12
49. C. Cordon-Cardo Molecular alterations associated with bladder cancer initiation and progression Scand J Urol Nephrol Suppl 218 2008 154 165
50. E.A. De Bruijn, H.P. Sleeboom, P.J. van Helsdingen Pharmacodynamics and pharmacokinetics of intravesical mitomycin C upon different dwelling times Int J Cancer 51 1992 359 364
51. M. Chai, M.G. Wientjes, R.A. Badalament, J.K. Burgers, J.L. Au Pharmacokinetics of intravesical doxorubicin in superficial bladder cancer patients J Urol 152 1994 374 378
52. M.G. Wientjes, R.A. Badalament, J.L. Au Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer Cancer Chemother Pharmacol 32 1993 255 262
53. E. Chiong, K. Esuvaranathan New therapies for non-muscle-invasive bladder cancer World J Urol 28 2010 71 78
54. M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen EAU guidelines on nonmuscle-invasive urothelial carcinoma of the bladder Eur Urol 54 2008 303 314
55. M.C. Hall, S.S. Chang, G. Dalbagni, R.S. Pruthi Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update J Urol 178 2007 2314 2330
56. C.N. Sternberg, S.M. Donat, J. Bellmunt, R.E. Millikan Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer Urology 69 2007 62 79
57. R.J. Sylvester, W. Oosterlinck, A.P. van der Meijden A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials J Urol 171 2004 2186 2190
58. A. Pawinski, R. Sylvester, K.H. Kurth, C. Bouffioux A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage Ta,T1 bladder cancer: European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer J Urol 156 1996 1934 1940
59. C. Bouffioux, K.H. Kurth, A. Bono Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment: European Organization for Research and Treatment of Cancer Genitourinary Group J Urol 153 1995 934 941
60. B. Ali-el-Dein, M. El-Baz, A.N.M. Aly, S. Shamaa, A. Ashamallah Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study J Urol 158 1997 68 73
61. F. Calais da Silva, F. Ferrito, T. Brandao 4-Epidoxorubicin versus mitomycin C intravesical chemoprophylaxis of superficial bladder cancer Eur Urol 21 1992 42 44
62. J.L. Au, R.A. Badalament, M.G. Wientjes Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial J Natl Cancer Inst 93 2001 597 604
63. S.M. Di Stasi, A. Giannantoni, R.L. Stephen Intravesical electromotive mitomycin-c versus passive transport mitomycin-c for high risk superficial bladder cancer: a prospective randomized study J Urol 170 2003 777 782
64. S.M. Di Stasi, A. Giannantoni, A. Giurioli Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial Lancet Oncol 7 2006 43 51
65. P. Gontero, L. Cattel, T. Paone, P. Milla Pharmacokinetic study to optimize the intravesical administration of gemcitabine BJU Int 106 2010 1652 1656
66. P. Gontero, C. Fiorito, I. Lucca, F. Valenteno, A. Tizzani New drugs currently available in nonmuscle invasive bladder cancer: update on gemcitabine studies Arch Ital Urol Andol 80 2008 162 164
67. D.D. Kuznetsov, N.F. Alsikafi, R.C. O'Connor, G. Steinberg Intravesical valrubicin in the treatment of carcinoma in situ of the bladder Expert Opin Pharmacother 2 2001 1009 1013
68. M.I. Walton, P.J. Smith, P. Workman The role of NAD(P)H: quinone reductase (EC 1.6.99.2, DT-diaphorase in the reductive bioactivation of the novel indoloquinone anti-tumor agent EO9 Cancer Commun 3 1991 199 206
69. R.M. Phillips, P.B. Hulbert, M.C. Bibby In vitro activity of the novel indoloquinone EO-9 and the inXuence of pH on cytotoxicity Br J Cancer 65 1992 359 364
70. K. Hendricksen, A.G. van der Heijden, E.B. Cornel Two year follow up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer World J Urol 27 2009 337 342
71. M.A. Laudano, L.J. Barlow, A.M. Murphy Long-term clinical outcomes of phase I trial of intravesical docitaxel in the management of non-muscle invasive bladder cancer refractory to standard intravesical therapy Urology 75 2010 134 137
72. A. Morales, D. Eidinger, A.W. Bruce Intracavity bacille Calmette-Guerin in the treatment of superficial bladder tumors J Urol 116 1976 180 183
73. R. Breban, A. Bisiaux, C. Biot, C.A. Rentsch, P. Bousso, M.L. Albert Mathematical model of tumor immunotherapy for bladder carcinoma identifies the limitations of the innate immune response Oncoimmunology 1 2012 9 17
74. W. Zhao, J.S. Schorey, M. Bong-Mastek Role of a bacillus Calmette-Guérin fibronectin attachment protein in BCG-induced antitumor activity Int J Cancer 86 2000 83 88
75. H. Suttmann, M. Jacobsen, K. Reiss Mechanisms of bacillus Calmette-Guerin mediated natural killer cell activation J Urol 172 2004 1490 1495
76. C.A. Power, G. Wei, P.A. Bretscher Mycobacterial dose defines the Th1/Th2 nature of the immune response independently of whether immunization is administered by the intravenous, subcutaneous, or intradermal route Infect Immun 66 1998 5743 5750
77. G.J. Fellows, M.K. Parmar, K.M. Grigor Marker tumor response to Evans and Pasteur bacille Calmette-Guérin in multiple recurrent pTa/pT1 bladder tumors: report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party) Br J Urol 73 1994 639 644
78. R.J. Sylvester, A.P.M. van der Meijden, D.L. Lamm Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials J Urol 168 2002 1964 1970
79. J.A. Martinez-Pineiro, L. Martinez-Pineiro, E. Solsona Club Urolo′gico Espanõl de Tratamiento Oncolo′gico (CUETO) Has a 3-fold decreased dose of bacillus Calmette-Gue′rin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial J Urol 174 2005 1242 1247
80. R.J. Sylvester, M.A. Brausi, W.J. Kirkels Long-term efficacy results of EORTC Genito-Urinary Group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isonizid in patients with intermediate and high risk stage Ta T1 urothelial carcinoma of the bladder Eur Urol 57 2010 766 773
81. D.L. Lamm, B.A. Blumenstein, J.D. Crissman Maintenance bacillus Calmette-Guérin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder; a randomized Southwest Oncology Group study J Urol 163 2000 1124 1129
82. H. Koga, S. Ozono, T. Tsushima BCG Tokyo Strain Study Group Maintenance intravesical bacillus Calmette-Guérin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group Int J Urol 17 2010 759 766
83. M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen EAU guidelines on non-muscle invasive urothelial carcinoma of the bladder, the 2011 update Eur Urol 59 2011 997 1008
84. www.eortc.be/tools/bladder calculator
85. P.-U. Malmström, R.J. Sylvester, D.E. Crawford An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gue′rin for non-muscle-invasive bladder cancer Eur Urol 56 2009 247 256
86. J. Bekisz, H. Schmeisser, J. Hernandez, N.D. Goldman, K.C. Zoon Human interferons alpha, beta and omega Growth Factors 22 2004 243 251
87. H.W. Herr, G. Dalbagni Defining bacillus Calmette-Guerin refractory superficial bladder tumors J Urol 169 2003 1706 1708